Lantheus Holdings Inc LNTH

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agentBEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Centers for Medicare & Medicaid

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancerBEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluati

FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...

Lantheus Holdings has delivered a powerful 5 year share price run, and the recent pullback leaves investors asking whether the current US$99.74 level is still grounded in the cash the business can generate. With fresh product news in its core radiopharmaceutical line, the question now is how far those future cash flows can stretch to back up today's valuation. Over the past 5 years the stock has returned 285.5%, which puts real pressure on the cash flow outlook to carry that kind of value...

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

Lantheus currently trades at $100.02 and has been a dream stock for shareholders. It’s returned 270% since September 2021, blowing past the S&P 500’s 74.5% gain. The company has also beaten the index over the past six months as its stock price is up 32.1% thanks to its solid quarterly results.

Approval of BRAVNETSA expands radioligand treatment options for adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs)BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Admini

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Committed debt financing supporting the previously announced acquisition of Lantheus Holdings by Curium includes a senior secured multicurrency revolving credit facility and a $4.25 billion senior secured term loan B facility, according to a regulatory filing. In addition, Curium Midco entered into a separate commitment letter for a $1.125 billion PIK facility. The TLB and revolver will be incurred as additional facilities under Curium BidCo’s existing credit agreement, with JPMorgan as administ

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare equipment and supplies industry, including Lantheus (NASDAQ:LNTH) and its peers.

BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on year to $388.2 million. Its non-GAAP profit of $1.55 per share was 18.9% above analysts’ consensus estimates.